Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell Sequential Allo-HSCT and Kidney Transplantation in the Treatment of SIOD

Inclusion Criteria:

1. Diagnosed as SIOD and was in stage 5 of chronic kidney disease

2. Having allogeneic HSCT indications, at least suitable donors (relatives) forhaploidentical allogeneic transplantation and kidneys from stem celltransplantation donors;

3. serum total bilirubin ≤ 1.5 times the upper limit of normal, and serum alanineaminotransferase (ALT) and aspartate aminotransferase (AST) were both ≤ 3 timesthe upper limit of the normal range.

4. Echocardiogram shows left ventricular ejection fraction (LVEF) ≥ 50%;

5. There is no active pulmonary infection, and the oxygen saturation during airinhalation is more than 92%；

6. Estimated survival time ≥ 3 months;

7. ECOG performance status 0 to 1;

8. Pregnant/lactating women, or male or female patients who have fertility and arewilling to take effective contraceptive measures at least 6 months after thelast cell infusion during the study period;

9. Those who voluntarily participated in this trial and provided informed consent;

Exclusion Criteria:

1. Allergic to pretreatment measures

2. received any containing ATG/ALG such IST、alemtuzumab、high-dose cyclophosphamide (≥ 45mg/kg/day) , received CsA treatment within 6 months, or usedthrombopoietin receptor (tpo-r) agonists in the past;

3. Patients with the history of epilepsy or other CNS disease;

4. Patients with prolonged QT interval time or severe heart disease;

5. Previous recipients of allogeneic hematopoietic stem cell transplantation ororgan transplantation

6. People infected with HIV, active hepatitis B or hepatitis C virus, and patientswith active infection who are not cured;

7. The proiferation rate is less than 5 times response to CD3/CD28 co-stimulationsignal;

8. Patients with malignant tumor;

9. People with other genetic diseases；

10. After receiving CD7 car-t treatment, patients who were unable to acceptsubsequent kidney transplantation due to severe infection or poor amplificationof car-t in vivo.

11. Any situation that researchers believe may increase the risk to the subjects orinterfere with the trial results.